Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study

References

• Brown JB, Nichols GA. Slow response to loss of glycemic control in Type 2 diabetes mellitus. Am J Manag Care 2003;9:213-17
   PubMed Web of Science ®Google Scholar
• Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-40
   PubMed Web of Science ®Google Scholar
• Korytkowski M, Niskanen L, Asakura T. FlexPen®: addressing issues of confidence and convenience in insulin delivery. Clin Ther 2005;27 (Suppl B):89-100
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Lauritzen T, et al; the International Dawn Advisory Panel. Resistance to insulin therapy among patients and providers results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-9
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Anderson BJ, Lohrer PA, et al. Insulin omission in women with IDDM. Diabetes Care 1994;17:1178-85
   PubMed Web of Science ®Google Scholar
• Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ 2007;33:1014-29
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81
   PubMed Web of Science ®Google Scholar
• Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-25
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Korytkowski M, Bell D, Jacobsen C, et al; the FlexPen® Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836-48
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16
   PubMed Web of Science ®Google Scholar
• Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins: an assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007;9:648-59
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M, Derezinski T, et al; the Levemir Treat-To-Target Study Group. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 2006;29:1269-74
   PubMed Web of Science ®Google Scholar
• Rašlová K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201
   PubMed Web of Science ®Google Scholar
• Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56-64
   PubMed Web of Science ®Google Scholar
• DeVries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of ? Diabetes Metab Res Rev 2007;23:441-54
   PubMed Web of Science ®Google Scholar
• Le Floch J-P, Lévy M, Mosnier-Pudar H, et al; the ADAPT™ Study Group. A comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal–bolus therapy for type 1 diabetes: the ADAPT™ Study. Diabetes Care 2008 [Epub ahead of print] PMID: 18945928
   Web of Science ®Google Scholar
• Klein O, Lynge J, Endahl L, et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007;9:290-9
   PubMed Web of Science ®Google Scholar
• Dornhorst A, Lüddeke H-J, Koenen C, et al; the PREDICTIVE Study Group. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE™. Diabetes Obes Metab 2008;10:75-81
   Google Scholar
• Lüddeke H-J, Sreenan S, Aczel S, et al. PREDICTIVE - a global, prospective, observational study to evaluate insulin detemir treatment in type 1 and 2 diabetes – baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007;9:428-34
   PubMed Web of Science ®Google Scholar
• UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
   PubMed Web of Science ®Google Scholar
• Holman RR, Thorne KI, Farmer AJ, et al; the 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Eng J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Raz I, Wilson P, Strojek K, et al. Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with type 2 diabetes mellitus (HEART2D). Diabetologia 2008;51(Suppl 1):S547
   Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Home PD, Boulton AJM, Jimenez J, et al. Issues relating to the early or earlier use of insulin in type 2 diabetes. Practical Diabetes Int 2003;20:63-71
   Google Scholar
• Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes Metab 2007;9:799-812
   PubMed Web of Science ®Google Scholar
• Hanaire H, Sreenan S, Dornhorst A, et al. Insulin-naïve patients with type 2 diabetes and higher BMI experience weight loss when initiated onto insulin detemir: 12-week, 26-week and 52-week follow-up data from PREDICTIVE™. Rome, Italy: 44th Annual Meeting of the European Association for the Study of Diabetes [Abstract 976]
   Google Scholar
• Rosenstock J, Davies M, Home PD, et al. Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycaemic control comparable to insulin glargine with less weight gain. Washington, DC: 66th Scientific Sessions of the American Diabetes Association, 2006 [Abstract 0555-P]
   Google Scholar
• Fakhoury W, Lockhart I, Kotchie RW, et al. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type 2 diabetes. Pharmacology 2008;82:156-63
   PubMed Web of Science ®Google Scholar
• Sreenan S, Landstedt-Hallin L, Koenen C, et al; the PREDICTIVE Study Group. OAD-treated, type 2 patients initiated on insulin detemir experience significant weight loss when SU or TZD are discontinued at insulin initiation: results from PREDICTIVE™. Chicago, IL: 67th Scientific Sessions of the American Diabetes Association, 2007 [Abstract 0549-P]
   Google Scholar
• Vijan S, Kent DM, Hayward RA. Are randomized controlled trials sufficient evidence to guide clinical practice in type II (non-insulin-dependent) diabetes ? Diabetologia 2000;43:125-30
   PubMed Web of Science ®Google Scholar
• Ligthelm RJ, Borz V, Gumprecht J, et al. Importance of observational studies in clinical practice. Clin Ther 2007;29:1284-92
   Web of Science ®Google Scholar